资料显示，呈和科技股份有限公司位于广东省广州市白云区北太路1633号广州民营科技园科强路2号， 成立日期2002年1月31日，上市日期2021年6月7日，公司主营业务涉及为制造高性能树脂材料与改性塑 料的企业提供环保、安全、高性能的高分子材料助剂产品。主营业务收入构成为：成核剂62.97%，合 成水滑石13.41%，贸易产品9.04%，抗氧剂8.04%，NDO复合助剂6.52%，其他(补充)0.02%。 截至9月30日，呈和科技股东户数5462.00，较上期增加27.80%；人均流通股34478股，较上期减少 21.75%。2025年1月-9月，呈和科技实现营业收入7.40亿元，同比增长14.16%；归母净利润2.28亿元，同 比增长15.09%。 分红方面，呈和科技A股上市后累计派现3.93亿元。近三年，累计派现3.03亿元。 1月29日，呈和科技跌0.66%，成交额2.99亿元。两融数据显示，当日呈和科技获融资买入额4893.39万 元，融资偿还3282.18万元，融资净买入1611.21万元。截至1月29日，呈和科技融资融券余额合计3.97亿 元。 融资方面，呈和科技当日融资买入4893.39万元。当前 ...

1月28日，呈和科技跌5.16%，截至发稿，报58.50元/股，成交1.26亿元，换手率1.12%，总市值110.17亿 元。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，任何在本文出现的信息（包括但 不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验，因此本文内 容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 数据显示，富国基金旗下1只基金位居呈和科技十大流通股东。富国沪港深业绩驱动混合型A （005847）三季度减持65.09万股，持有股数188.64万股，占流通股的比例为1%。根据测算，今日浮亏 损失约599.89万元。 富国沪港深业绩驱动混合型A（005847）成立日期2018年7月27日，最新规模31.19亿。今年以来收益 11.28%，同类排名1607/8864；近一年收益56.28%，同类排名1667/8126；成立以来收益165.9%。 富国沪港深业绩驱动混 ...

Core Insights - Chenghe Technology experienced a decline of 5.05% on November 21, with a stock price of 36.07 CNY per share and a total market capitalization of 6.793 billion CNY [1] Company Overview - Chenghe Technology Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on January 31, 2002. The company went public on June 7, 2021. Its main business involves providing environmentally friendly, safe, and high-performance polymer material additives for manufacturers of high-performance resin materials and modified plastics [1] - The revenue composition of Chenghe Technology includes: nucleating agents (62.97%), synthetic hydrotalcite (13.41%), trading products (9.04%), antioxidants (8.04%), NDO composite additives (6.52%), and others (0.02%) [1] Shareholder Information - Among the top ten circulating shareholders of Chenghe Technology, a fund under the Fortune Fund ranks as a significant shareholder. The Fortune Hong Kong-Shenzhen Performance Driven Mixed A Fund (005847) reduced its holdings by 650,900 shares in the third quarter, now holding 1.8864 million shares, which accounts for 1% of the circulating shares. The estimated floating loss today is approximately 3.622 million CNY [2] - The Fortune Hong Kong-Shenzhen Performance Driven Mixed A Fund was established on July 27, 2018, with a current scale of 4.474 billion CNY. Year-to-date returns are 40.67%, ranking 1375 out of 8136 in its category; the one-year return is 41.85%, ranking 1010 out of 8056; and since inception, the return is 137.72% [2]

Group 1 - The core point of the news is that Chenghe Technology's stock price has dropped by 5.05%, currently trading at 36.07 CNY per share, with a total market capitalization of 6.793 billion CNY [1] - Chenghe Technology, established on January 31, 2002, and listed on June 7, 2021, specializes in providing high-performance polymer material additives for manufacturers of resin materials and modified plastics [1] - The main revenue composition of Chenghe Technology includes nucleating agents (62.97%), synthetic hydrotalcite (13.41%), trading products (9.04%), antioxidants (8.04%), NDO composite additives (6.52%), and others (0.02%) [1] Group 2 - From the perspective of major fund holdings, Jiahe Fund has one fund heavily invested in Chenghe Technology, specifically the Jiahe Steady Growth Mixed A fund, which reduced its holdings by 9,069 shares in the third quarter [2] - The Jiahe Steady Growth Mixed A fund currently holds 30,400 shares, accounting for 3.93% of the fund's net value, ranking it as the sixth-largest holding [2] - The fund has a total scale of 14.6236 million CNY and has achieved a year-to-date return of 11.52%, ranking 5,368 out of 8,136 in its category [2]

Investment Rating - The investment rating for the company is "Buy" and is maintained [9]. Core Insights - The company reported a revenue of 740 million yuan for the first three quarters of 2025, representing a year-on-year increase of 14.2%. The net profit attributable to shareholders was 230 million yuan, up 15.1% year-on-year, and the net profit after deducting non-recurring gains and losses was 220 million yuan, an increase of 11.7% year-on-year. In Q3 alone, the revenue was 270 million yuan, reflecting a year-on-year growth of 14.8% and a quarter-on-quarter increase of 7.2% [2][6]. - The company is a leading domestic producer of nucleating agents and synthetic hydrotalcite, with aspirations to become a global leader in polymer material solutions. Its core products are gradually replacing imports in the domestic market and are competitive internationally [12]. - The company's gross margin for Q1 to Q3 of 2025 was 45.4%, a year-on-year increase of 0.4 percentage points, while the net margin was 30.8%, up 0.2 percentage points. The operating expense ratio decreased to 9.3%, down 0.4 percentage points year-on-year, driven by reductions in sales and management expense ratios [12]. - The completion of the IPO project and the full operation of the Nansha plant have further enhanced the company's production capacity, adding significant new capacity for nucleating agents and synthetic hydrotalcite [12]. - The company achieved rapid growth in overseas revenue, reaching 120 million yuan in H1 2025, a year-on-year increase of 70.1%. This growth is attributed to the company's international strategy and its ability to meet overseas customer demands [12]. - The company emphasizes shareholder returns, with a mid-year dividend of 43 million yuan announced for 2025, maintaining a payout ratio between 30% and 35% since 2020 [12]. - The company is focused on the polymer material additives sector and has strong competitiveness in antioxidant and NDO composite additives. The domestic market for nucleating agents and synthetic hydrotalcite has low penetration, indicating potential for market share growth [12]. Financial Summary - For 2025, the company forecasts total revenue of 1.058 billion yuan, with net profits projected at 297 million yuan, 333 million yuan, and 377 million yuan for the years 2025, 2026, and 2027 respectively [17].

Core Viewpoint - Chenghe Technology's stock experienced a slight decline of 0.68% on October 9, with a trading volume of 157 million yuan, indicating a high level of market activity and investor interest [1]. Financing Summary - On October 9, Chenghe Technology had a financing buy-in amount of 21.58 million yuan and a financing repayment of 27.21 million yuan, resulting in a net financing outflow of 5.63 million yuan [1]. - The total financing and securities lending balance for Chenghe Technology reached 277 million yuan, accounting for 3.90% of its circulating market value, which is above the 80th percentile of the past year, indicating a high level of financing activity [1]. - There were no shares sold or repaid in the securities lending market on October 9, with the securities lending balance also at zero, placing it in the 90th percentile of the past year [1]. Business Performance - As of June 30, Chenghe Technology reported a total of 4,274 shareholders, an increase of 30.07% from the previous period, with an average of 44,061 circulating shares per shareholder, up by 6.99% [2]. - For the first half of 2025, Chenghe Technology achieved operating revenue of 471 million yuan, representing a year-on-year growth of 13.77%, and a net profit attributable to shareholders of 147 million yuan, reflecting a 15.33% increase year-on-year [2]. Dividend Information - Since its A-share listing, Chenghe Technology has distributed a total of 393 million yuan in dividends, with 303 million yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders of Chenghe Technology, the "Fuguo HuGangShen Performance Driven Mixed A" fund ranked as the eighth largest shareholder with 2.54 million shares, an increase of 653,600 shares from the previous period [3]. - The "Fuguo Tianhui Growth Mixed (LOF) A/B" fund ranked ninth, holding 2.50 million shares, which is a decrease of 350,000 shares compared to the previous period [3].

Investment Rating - The report maintains a "Buy-B" rating for the company [5] Core Views - The company achieved steady revenue growth in the first half of 2025, with total revenue of 471 million yuan, up 13.77% year-on-year, and a net profit of 147 million yuan, up 15.33% year-on-year [1][2] - The company is actively seizing market opportunities, accelerating product innovation, and expanding its application downstream, which has led to increased market share and steady performance growth [2] - The modified plastics industry has significant growth potential, and the nucleating agent sector is at a critical stage of domestic substitution, with the company positioned to lead in high-performance nucleating agents [3][4] Financial Performance - In the first half of 2025, the nucleating agent segment generated 297 million yuan in revenue, while synthetic talc, NDO composite additives, and antioxidants contributed 63 million yuan, 31 million yuan, and 38 million yuan, respectively [2] - The company's overseas revenue reached 120 million yuan, indicating strong international market performance [2] - The gross margin for the first half of 2025 was 45.79%, an increase of 0.7 percentage points year-on-year, while the expense ratio was 10.46%, up 1.63 percentage points year-on-year [2] Industry Outlook - From 2019 to 2023, China's modified plastics production increased from 19.55 million tons to 29.75 million tons, with a compound annual growth rate of 11.07%, indicating a robust growth trajectory for the industry [3] - The high-end modified plastics market in China still relies heavily on imports, and the industry is currently at a pivotal point for domestic substitution [3] Investment Projections - The projected net profits for 2025, 2026, and 2027 are 277 million yuan, 336 million yuan, and 380 million yuan, respectively, with corresponding price-to-earnings ratios of 23.2, 19.2, and 17 times [5][9]

Investment Rating - The investment rating for the company is "Buy" and it is maintained [10] Core Views - The company achieved a revenue of 471 million yuan in the first half of 2025, representing a year-on-year increase of 13.8%, and a net profit attributable to shareholders of 147 million yuan, up 15.3% year-on-year [2][7] - In Q2 alone, the company generated a revenue of 251 million yuan, which is a 12.7% increase year-on-year and a 14.0% increase quarter-on-quarter [2][7] - The company's main products, nucleating agents and synthetic hydrotalcite, are key raw materials for producing high-performance resins, and the domestic substitution is accelerating amid global trade policy fluctuations [13] - The company has completed its IPO project and fully utilized its Nansha plant, enhancing its production capacity significantly [13] - The overseas revenue reached 120 million yuan in the first half of 2025, marking a substantial growth of 70.1% year-on-year, indicating a strong international strategy [13] - The company aims to become a "definer" of comprehensive solutions in high polymer materials, enhancing customer satisfaction and loyalty through customized services [13] - The company is a leader in the domestic nucleating agent and synthetic hydrotalcite market, with potential for continued market share growth [13] Financial Summary - The company forecasts net profits of 297 million yuan, 348 million yuan, and 401 million yuan for the years 2025, 2026, and 2027 respectively [13] - The total revenue is projected to reach 1.058 billion yuan in 2025, with a gross profit margin of 44% [19] - The company’s net profit margin is expected to be around 28.1% in 2025 [19]

Investment Rating - The investment rating for the company is "Outperform the Market" [5][3][19] Core Views - The company achieved steady growth in net profit in the first half of 2025, with a revenue of 471 million yuan, representing a year-on-year increase of 13.77%, and a net profit of 147 million yuan, up 15.33% year-on-year. The growth is attributed to the increased domestic market penetration and localization of polymer material additives [1][9][10] - The company is the largest domestic seller of nucleating agents and is positioned to benefit from the increasing domestic substitution rate due to rising international trade tensions. The nucleating agent market is expected to exceed 1 billion USD globally by 2025 [2][18] - The company plans to continue seeking strategic acquisitions to enhance its competitive strength and promote high-quality development, despite the recent termination of a planned acquisition of a leading ITO target material company [2][18] Financial Performance Summary - In the first half of 2025, the nucleating agent segment generated 297 million yuan in revenue, a 17.29% increase year-on-year, accounting for 62.97% of total revenue with a gross margin of 56.05% [10] - The company’s revenue forecast for 2025-2027 is adjusted to 301 million, 350 million, and 402 million yuan respectively, with diluted EPS of 1.60, 1.86, and 2.13 yuan [3][19] - The company’s overall sales gross margin was 45.79%, with a net profit margin of 31.26% in the first half of 2025, reflecting a year-on-year improvement [9][10] Business Segmentation - The nucleating agent segment is the largest contributor to revenue, followed by synthetic hydrotalcite and antioxidant segments, with significant growth observed in the antioxidant segment, which saw a 129% year-on-year increase in revenue [10] - International revenue reached 120 million yuan, a 70.08% increase year-on-year, indicating strong overseas market performance [10] Market Outlook - The company is well-positioned to capitalize on the growing demand for nucleating agents and synthetic hydrotalcite, with a focus on expanding both domestic and international markets [2][18] - The anticipated increase in the domestic substitution rate for nucleating agents is expected to accelerate due to international trade risks, providing further growth opportunities for the company [2][18]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [10][12]. Core Insights - The company is a leader in the domestic nucleating agent and synthetic hydrotalcite market, with strong competitiveness in antioxidant and NDO composite additives. The penetration rate of domestic nucleating agents and synthetic hydrotalcite remains low, indicating potential for continued growth in the company's main business. Projected net profits for 2025, 2026, and 2027 are estimated at 360 million, 439 million, and 518 million yuan respectively [3][10]. Company Overview - The company has been deeply engaged in the polymer material additive sector for over 20 years, establishing itself as a leader in nucleating agents and synthetic hydrotalcite. It has successfully developed and marketed nucleating agent products, gaining recognition from major downstream manufacturers and expanding into both domestic and international markets [6][22]. Nucleating Agents - The demand for nucleating agents is growing significantly, with domestic demand increasing from 4,600 tons in 2016 to 9,520 tons in 2022, reflecting a compound annual growth rate of 12.9%. In 2023, China's nucleating agent demand accounted for approximately 27% of the global market, second only to North America [7][61]. - The company benefits from a competitive edge as domestic nucleating agent prices are generally 1/3 to 1/2 lower than imported products, driven by lower production costs and reduced logistics expenses [7]. Synthetic Hydrotalcite - Synthetic hydrotalcite is primarily used as a heat stabilizer in PVC production and as a halogen absorber in polyolefin resin production. The demand for synthetic hydrotalcite has maintained rapid growth, with domestic leading companies achieving technological breakthroughs and accelerating import substitution [8][24]. Antioxidants - In 2023, the company entered the antioxidant sector through acquisitions, enhancing its product line. The antioxidant products are primarily specialized hindered phenolic antioxidants, widely used in various applications including nylon and polyurethane [9][10]. Financial Analysis - The company has shown steady revenue growth, with significant contributions from its core products, particularly nucleating agents. From 2018 to 2024, the sales volume of nucleating agents increased from 2,349 tons to 9,728 tons, a growth rate exceeding 314% [38][43]. - The company maintains a high gross margin, consistently above 40%, and has optimized its expense structure, enhancing its market competitiveness and profitability [45][52]. Investment Recommendations - Given the company's strong market position, growth potential in nucleating agents and synthetic hydrotalcite, and the recent expansion into antioxidants, the report recommends a "Buy" rating for investors looking for opportunities in the polymer additive sector [10][12].